Alex Pye discusses the investment thesis for Abzena on the back of his recent initiation report. Alex believes that the Abzena has a stable underlying core protein services business, together with the expanded service offering following two recent acquisitions that give an increased exposure to the US, and that there is significant value upside potential for the business.
